These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38386285)

  • 1. Biodistribution of Radioactively Labeled Splice Modulating Antisense Oligonucleotides After Intracerebroventricular and Intrathecal Injection in Mice.
    Metz T; Welling MM; Suidgeest E; Nieuwenhuize E; de Vlaam T; Curtis D; Hailu TT; van der Weerd L; van Roon-Mom WMC
    Nucleic Acid Ther; 2024 Feb; 34(1):26-34. PubMed ID: 38386285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.
    van de Steeg E; Läppchen T; Aguilera B; Jansen HT; Muilwijk D; Vermue R; van der Hoorn JW; Donato K; Rossin R; de Visser PC; Vlaming MLH
    Nucleic Acid Ther; 2017 Aug; 27(4):221-231. PubMed ID: 28418733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution and Penetration of Intracerebroventricularly Administered 2'OMePS Oligonucleotide in the Mouse Brain.
    Casaca-Carreira J; Temel Y; Larrakoetxea I; Jahanshahi A
    Nucleic Acid Ther; 2017 Feb; 27(1):4-10. PubMed ID: 27753537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.
    van Deutekom J; Beekman C; Bijl S; Bosgra S; van den Eijnde R; Franken D; Groenendaal B; Harquouli B; Janson A; Koevoets P; Mulder M; Muilwijk D; Peterburgska G; Querido B; Testerink J; Verheul R; de Visser P; Weij R; Aartsma-Rus A; Puoliväli J; Bragge T; O'Neill C; Datson NA
    Nucleic Acid Ther; 2023 Jun; 33(3):193-208. PubMed ID: 37036788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convective forces increase rostral delivery of intrathecal radiotracers and antisense oligonucleotides in the cynomolgus monkey nervous system.
    Sullivan JM; Mazur C; Wolf DA; Horky L; Currier N; Fitzsimmons B; Hesterman J; Pauplis R; Haller S; Powers B; Tayefeh L; DeBrosse-Serra B; Hoppin J; Kordasiewicz H; Swayze EE; Verma A
    J Transl Med; 2020 Aug; 18(1):309. PubMed ID: 32771027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exonic sequences provide better targets for antisense oligonucleotides than splice site sequences in the modulation of Duchenne muscular dystrophy splicing.
    Aartsma-Rus A; Houlleberghs H; van Deutekom JC; van Ommen GJ; 't Hoen PA
    Oligonucleotides; 2010 Apr; 20(2):69-77. PubMed ID: 20377429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms.
    Aartsma-Rus A; van Vliet L; Hirschi M; Janson AA; Heemskerk H; de Winter CL; de Kimpe S; van Deutekom JC; 't Hoen PA; van Ommen GJ
    Mol Ther; 2009 Mar; 17(3):548-53. PubMed ID: 18813282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models.
    Saoudi A; Fergus C; Gileadi T; Montanaro F; Morgan JE; Kelly VP; Tensorer T; Garcia L; Vaillend C; Muntoni F; Goyenvalle A
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Luna Velez MV; Paulino da Silva Filho O; Verhaegh GW; van Hooij O; El Boujnouni N; Brock R; Schalken JA
    Prostate; 2022 May; 82(6):657-665. PubMed ID: 35098567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of Antisense Oligonucleotides to the Mouse Brain by Intracerebroventricular Injections.
    Metz T; Kuijper EC; van Roon-Mom WMC
    Methods Mol Biol; 2022; 2434():333-341. PubMed ID: 35213029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.
    Maruyama R; Touznik A; Yokota T
    J Vis Exp; 2018 May; (135):. PubMed ID: 29806836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain.
    Chauhan NB
    Antisense Nucleic Acid Drug Dev; 2002 Oct; 12(5):353-7. PubMed ID: 12477284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice.
    Verhaart IE; Tanganyika-de Winter CL; Karnaoukh TG; Kolfschoten IG; de Kimpe SJ; van Deutekom JC; Aartsma-Rus A
    Nucleic Acid Ther; 2013 Jun; 23(3):228-37. PubMed ID: 23634945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing Effective Antisense Oligonucleotides for Exon Skipping.
    Shimo T; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Oligonucleotide Design and Evaluation of Splice-Modulating Properties Using Cell-Based Assays.
    Slijkerman R; Kremer H; van Wijk E
    Methods Mol Biol; 2018; 1828():519-530. PubMed ID: 30171565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS.
    Wahlestedt C; Khorkova O
    Cell Mol Neurobiol; 2021 Jul; 41(5):849-853. PubMed ID: 32656646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
    Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
    Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
    Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview on AON design.
    Aartsma-Rus A
    Methods Mol Biol; 2012; 867():117-29. PubMed ID: 22454058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.